Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.52 |
| ▸ | TTK | P33981 | 4/20 | 0.52 |
| ▸ | ULK1 | O75385 | 2/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | STK4 | Q13043 | 1/20 | 0.48 |
| ▸ | STK3 | Q13188 | 1/20 | 0.48 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.48 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.48 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086534 | 1.00 | EGFR (0.56) | EGFRALKINSRLRRK2TTK | |
| SCHEMBL30086686 | 0.88 | IGF1R (0.50) | EGFRIGF1R | |
| SCHEMBL30086958 | 0.88 | IGF1R (0.50) | EGFRIGF1R | |
| SCHEMBL23906833 | 0.88 | IGF1R (0.50) | EGFRIGF1R | |
| SCHEMBL23906697 | 0.88 | IGF1R (0.50) | EGFRIGF1R | |
| SCHEMBL23887678 | 0.85 | PLK4 (0.65) | EGFRINSRTTKPTK2FGFR3 | |
| SCHEMBL30086328 | 0.85 | PLK4 (0.65) | EGFRINSRTTKPTK2FGFR3 | |
| SCHEMBL23906239 | 0.83 | IGF1R (0.63) | IGF1RZAP70 | |
| SCHEMBL30086558 | 0.83 | IGF1R (0.63) | IGF1RZAP70 | |
| SCHEMBL23906230 | 0.82 | CDK4 (0.51) | EGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | EGFR 545/4885ALK 1/4885INSR 477/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | EGFR 545/4885ALK 1/4885INSR 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.